Pembrolizumab plus olaparib may improve PSA response in mCRPC, regardless of HRR mutation status

Investigators also found high concordance between the Guardant Health (360 or Omni) assays and FoundationOne CDx for the detection of BRCA and HRR mutations.

Frontline immunotherapy benefit in favorable-risk advanced RCC remains inconclusive

Additional prospective trials containing a larger sample size and longer follow up are needed to determine the optimal treatment sequence in favorable-risk advanced renal cell carcinoma.

Real-world results suggest survival advantage with cabozantinib versus axitinib in pretreated kidney cancer

The retrospective cohort study assessed outcomes in patients with advanced renal cell carcinoma who received cabozantinib or axitinib in the second-line setting or beyond.